comparative assessment of intramuscular progesterone and intravaginal progesterone to support luteal phase in IVF cycle

This study was designed to compare the benefits of intramuscular progesterone, 100mg daily, and cyclogest suppository, 400 mg BID, to support luteal phase in IVF cycle. In this Clinical Trial study 162 patients, between 20-40 years, were selected for rapid Zift cycles. Seventy seven cases used 400mg cyclogest suppository BID and 88 used 100 mg daily intramuscular progestron to support luteal phase. Age, duration of infertility, number of follicles and number of embryos were the variables which were assessed. Pregnancy rate and abortion rate were also compared between the two groups who underwent the treatment. Frequency of chemical pregnancy [postitive beta-HCG] was 27.3% in cyclogest and 30.6% in intramuscular progesterone group and there was no significant difference between two groups [NS]. Clinical pregnancy, according to sonography findings on 5[th] week, was seen in 22.1% of cyclogest and 27.1% of intramuscular progesterone group [NS]. Frequency of ongoing pregnancy was 15.6% in cyclogest and 18.5% in intramuscular progesterone group and there was no significant difference between two groups [NS]. In this study, the frequency of pregnancy, including chemical and clinical pregnancy, in intramuscular progesterone group was more than cyclogest group, whereas there was no significant statistical difference between two groups with regard to the number of cases. Therefore, we need to assess the study with more cases

comparison between intravenous magnesium sulfate and oral magnesium chloride in mild preeclampsia

Preeclampsia is the second cause of maternal mortality in the United States and accounts for 25% of perinatal mortality. Mild Preeclampsia could be treated without hospitalization, however in some cases, hospitalization seems necessary. Administration of magnesium sulfate [MgSo4] in mild preeclampsia is a matter of controversy. It is obvious that replacing intravenous magnesium sulfate with an oral preparation of magnesium, of course if it gains a sufficiently high serum level, can be easier to use and less expensive. Up to the present time, we have not been able to find any previously done studies using oral magnesium preprations to treat preeclampsia. Thus, we tried to compare serum magnesium level with oral magnesium chloride and intravenous [IV] magnesium sulfate therapy. This was a comparative experimental study. From January 2002 until April 2003, pregnant patients with mild preeclampsia admitted to Al-Zahra and Beheshti hospitals,Isfahan,Iran, between their 27 th and 38 th weeks of gestation were divided into 2 groups randomly. There were 33 patients in each group. The first group was treated with IV magnesium sulfate [2 g/h] and the second group received oral magnesium chloride [4 g/2h]. Magnesium level was checked in 0, 3, 6, 12 hours. The collected data were analyzed with t-Student test on a computer applying SPSS software. There was no statistical difference between the two groups regarding age, gravidity and gestational age. Magnesium level rose in both groups [P<0.01]. Increase of magnesium level in IV magnesium sulfate group was greater than in the other group, and in the magnesium chloride group, therapeutic level could not be achieved. Increase of serum Mg level in IV Mg sulfate group and reaching the therapeutic level was the same as reported before. Increase of Mg level with oral Mg chloride, though measurable, did not reach the therapeutic level. Perhaps with more cases or higher amounts of the drug or other types of Mg preparations we could reach the therapeutic level